Cyclacel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Bio Green Med Solution

10/08/2022 22:03

* Cyclacel Pharmaceuticals Inc  CYCC.OQ  reported a
quarterly
adjusted loss of 46 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 63 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cyclacel Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 46 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cyclacel Pharmaceuticals Inc shares had risen by 20.8%
this
quarter and lost 66.5% so far this year.
    * The company reported a quarterly loss of $4.63 million.
    * Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $19.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.63          -0.46          Beat
 Mar. 31 2022      -0.68          -0.42          Beat
 Dec. 31 2021      -0.65          -0.54          Beat
 Sep. 30 2021      -0.65          -0.54          Beat